Atomo Diagnostics Limited (ASX:AT1)

Market Cap	15.42M
Revenue (ttm)	4.22M
Net Income (ttm)	-6.45M
Shares Out	770.84M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,376,056
Average Volume	1,710,258
Open	0.0160
Previous Close	0.0160
Day's Range	0.0160 - 0.0250
52-Week Range	0.0140 - 0.0270
Beta	0.95
RSI	78.25
Earnings Date	Jul 31, 2025

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers rapid diagnostic test devices for HIV screening, pregnancy test, and respiratory test. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 85
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AT1

Financial Performance

In 2024, Atomo Diagnostics's revenue was 4.09 million, an increase of 60.65% compared to the previous year's 2.54 million. Losses were -6.85 million, -31.23% less than in 2023.